Tumors Metastatic to Brain Clinical Trial
Official title:
A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)
This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Objective: For cohort A and Cohort C, to determine the central nervous system (CNS) disease control rate (number of patients with stable disease or partial response or complete response / total number of treated patients) at 12 weeks following treatment with etirinotecan pegol in patients with advanced non-small cell lung cancer (NSCLC) or with metastatic brain cancer (mBC) with refractory brain metastases Secondary Objectives: Cohorts A and C: - To measure the overall disease control rate and response rate for patients receiving study therapy - To measure the systemic (non-CNS) disease control rate and response rate for patients receiving study therapy - To observe the progression free survival of the study population - To observe the overall survival of the study population Cohort B: • To observe CNS and systemic disease control in small cell lung cancer (SCLC) Cohorts A, B and C: • To determine the safety profile of etirinotecan pegol ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02107755 -
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
| Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
| Completed |
NCT00098605 -
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
|
Phase 2 | |
| Completed |
NCT00072163 -
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
|
Phase 2 | |
| Completed |
NCT01703507 -
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
|
Phase 1 | |
| Completed |
NCT00033254 -
Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
|
Phase 3 | |
| Active, not recruiting |
NCT01706432 -
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
|
||
| Recruiting |
NCT01891318 -
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
|
Phase 1/Phase 2 | |
| Suspended |
NCT01843413 -
Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
|
N/A | |
| Completed |
NCT01276210 -
Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
|
Phase 1 | |
| Completed |
NCT01234740 -
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
|
Phase 1 | |
| Terminated |
NCT00937482 -
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
|
Phase 1 | |
| Terminated |
NCT02269111 -
Quantitative MRI in Assessing Disease in Patients With Brain Tumors
|
N/A | |
| Withdrawn |
NCT02277561 -
Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery
|
N/A | |
| Completed |
NCT00992602 -
Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT02145910 -
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
|
Phase 1 |